Company intelligence / Profile preview

NovaBridge Biosciences

Ownership: Public · NBP
Development stage: Other

Overview

NovaBridge Biosciences (formerly I-Mab) is a global biotech platform company with a pipeline that includes advanced clinical-stage assets targeting oncology and ophthalmology. Key programs such as VIS-101 (bifunctional biologic, Phase 2 for wet AMD/DME; expected Phase 3-ready 2026), Givastomig (bispecific antibody, Phase 1b for gastric cancer), and Uliledlimab (anti-CD73, Phase 2 oncology) show promising early to mid-stage clinical results, with plans for global Phase 2 trials and strategic expansion in Asian and global markets[4][6][9].

Therapeutic areas: OncologyOphthalmology
Modalities: Bifunctional biologicBispecific antibodyMonoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

givastomig

1 more asset in the full pipeline.

Financials

Market cap: $104.7M
Total revenue: $0
Enterprise value: $-81.7M

Beyond the preview

Go deeper on NovaBridge Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaBridge Biosciences.